Weihai Baihe Biology Technological Co., Ltd. Class A

Weihai Baihe Biology Technological Co., Ltd. Class A

SSSE:603102
31.78
CNY
-0.28
(-0.87%)
2.04EPS
20.54P/E
2.39BMarket Cap
Apr 21Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.6
8.84
10.54
10.42
12.06
13.77
11.58
13.6
12.54
14.54
15.85
Basic EPS, GAAP
1.28
1.33
1.55
1.55
2.65
3.08
2.2
2.64
2.18
2.05
1.82
Free Cash Flow per Basic Share
- -
1.22
0.57
2.11
2.42
0.93
1.62
1.52
0.51
2.08
- -
Dividend per Share
- -
0.32
0.3
0.49
0.49
0.3
0.51
0.6
0.74
0.75
- -
Book Value per Share
6.3
7.33
8.59
9.63
12.08
14.87
22.22
23.66
25.09
25.87
26.37
Tangible Book Value per Share
5.91
6.87
8.15
9.19
11.67
14.39
21.79
22.96
24.31
24.5
25.06
Basic Weighted Avg Shares
48
48
48
48
48
48
63
64
64
63
62
Sales/Revenue/Turnover
365
423
507
500
578
662
725
871
801
911
989
Operating Margin (%)
19.05
18.51
17.4
19.35
26.26
25.45
20.59
21.05
18.51
16.46
15.94
Depreciation Expense
- -
16
19
21
21
24
33
38
41
46
- -
Net Income, GAAP
62
64
75
74
127
148
138
169
139
128
113
Effective Tax Rate (%)
14.04
13.39
13.66
14.52
14.12
12.57
12.88
12.59
13.41
12.12
13.36
Profit Margin (%)
16.85
15.04
14.71
14.88
21.98
22.37
19
19.4
17.38
14.1
11.46
Working Capital
147
174
212
265
379
389
1,090
1,122
1,161
1,180
1,236
LT Debt
- -
- -
- -
- -
2
2
2
- -
- -
11
14
Total Equity
303
352
412
462
580
714
1,422
1,514
1,606
1,686
1,724
Return on Invested Capital (%)
- -
19.11
19.33
18.09
23.99
21.96
12.91
11.5
8.85
7.99
7.46
Return on Capital (%)
- -
19.46
19.54
17.01
24.32
22.79
12.88
11.5
8.93
7.45
5.88
Return on Common Equity (%)
- -
19.46
19.54
17.01
24.39
22.88
12.91
11.51
8.93
7.88
6.74

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
11
15
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
2,637
2,020
2,387

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,427
1,461
1,455
Cash, Cash Equivalents & STI
1,092
1,127
1,102
Accounts Receivable, Net
111
105
100
Inventories
137
141
162
Total Current Liabilities
217
212
219
Payables & Accruals
- -
- -
- -
ST Debt
4
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
27.96%
4.99%
Free Cash Flow
- -
58.73%
298.29%
Net Income, GAAP
- -
1.36%
-7.81%
Sales/Revenue/Turnover
- -
9.96%
13.67%
Total Cash Common Dividend
- -
25.07%
-1.12%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
189
223
194
195
801
2025
207
213
- -
266
911
2026
252
252
220
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.54
0.76
0.54
0.36
2.18
2025
0.55
0.58
- -
0.47
2.05
2026
0.46
0.53
0.35
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
-0.01
0.74
2025
- -
- -
- -
- -
0.75
2026
- -
- -
- -
- -
- -

Company Description

CEO
Xin Li Liu
Full Time Employees
1,096
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Weihai China
IPO Date
Jan 25, 2022
Business
Weihai Baihe Biology Technological Co., Ltd. engages in the research, development, production, and commercialization of nutritional foods, dietary supplements, and functional health products. Founded in 2005 and headquartered in Rongcheng, Weihai, Shandong Province, China, the company operates both as a contract development and manufacturing organization (CDMO/OEM/ODM) and as an owner-brand producer. The company offers an extensive product portfolio spanning multiple delivery formats and wellness categories, including softgels, hard capsules, tablets, functional gummies, powders, granules, oral liquids, drops, and nutritional beverages; specialized health formulations tailored for infants, children, seniors, pregnant and lactating women, and athletic populations; customized nutritional formulas and dietary supplements; pet nutritional food and wellness supplements; and turnkey contract manufacturing services encompassing formulation research, regulatory registration, lab testing, blending, and automated packaging. The company markets proprietary brands, including Biohek, Hongyangshen, Yunyangyan, Forzal, Zulixing, and Nengbeijian, while supplying customized private-label solutions to healthcare brands, pharmaceutical distributors, e-commerce retailers, and supermarket chains. Weihai Baihe Biology maintains operations across mainland China and exports products to more than 70 countries and regions throughout Europe, North America, Southeast Asia, and Australasia. In recent strategic and operational developments, the company has expanded its global manufacturing presence through cross-border investments, including an agreement to acquire a majority 56% stake in New Zealand-based health supplement manufacturer OraNutrition; continued the expansion and digital automation of its intelligent production plants to enhance high-volume daily output across dosage forms; diversified product lines deeper into specialized pet health nutrition and innovative functional delivery forms; and implemented corporate share repurchase programs to optimize its capital management.